| |
|
|
| |
You are here: Home: BCU 9 | 2005: CME Information
|
|
| |
|
|
| |
 |
Breast Cancer Update - A CME Audio Series and Activity |
|
STATEMENT OF NEED/TARGET AUDIENCE
Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from a plethora of
ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications
for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation
— the practicing medical oncologist must be well informed of these advances. To bridge the gap between research
and patient care, Breast Cancer Update uses one-on-one discussions with leading oncology investigators. By
providing access to the latest research developments and expert perspectives, this CME program assists medical
oncologists in the formulation of up-to-date clinical management strategies.
GLOBAL LEARNING OBJECTIVES
- Critically evaluate the clinical implications of emerging clinical trial data in breast cancer treatment and incorporate
these data into management strategies in the adjuvant, neoadjuvant, metastatic and preventive settings.
- Counsel appropriately selected patients about the availability of ongoing clinical trials.
- Counsel postmenopausal patients with ER-positive breast cancer about the risks and benefits of adjuvant
aromatase inhibitors and of sequencing aromatase inhibitors after tamoxifen, and counsel premenopausal women
about the risks and benefits of adjuvant ovarian suppression alone or with other endocrine interventions.
- Describe and implement an algorithm for HER2 testing and treatment of patients with HER2-positive breast
cancer in the adjuvant, neoadjuvant and metastatic settings.
- Evaluate the emerging data on various adjuvant chemotherapy approaches, including dose-dense treatment
and the use of taxanes, and explain the absolute risks and benefits of adjuvant chemotherapy regimens to
patients.
- Counsel appropriate patients with metastatic disease about selection and sequencing of endocrine therapy
and about the risks and benefits of combination versus single-agent chemotherapy.
- Describe the computerized risk models and genetic markers to determine prognostic information on the
quantitative risk of breast cancer relapse, and when applicable, utilize these to guide therapy decisions.
PURPOSE OF THIS ISSUE OF BREAST CANCER UPDATE
The purpose of Issue 9 of Breast Cancer Update is to support these global objectives by offering the perspectives
of Drs Burstein, Dresdner, Levine, Mamounas, Siegel and Vogel on the integration of emerging clinical research
data into the management of breast cancer.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 4.5 category 1 credits toward the
AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in
the activity.
HOW TO USE THIS MONOGRAPH
This CME activity contains both audio and print components. To receive credit, the participant should listen to the
CDs or tapes, review the monograph and complete the post-test and evaluation form located in the back of this
monograph or on our website. This monograph contains edited comments, clinical trial schemas, graphics and
references that supplement the audio program. www.BreastCancerUpdate.com includes an easy-to-use interactive
version of this monograph with links to relevant full-text articles, abstracts, trial information and other web
resources indicated here in blue underlined text.
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
